Skip to main content

Table 1 Clinical trials of entospletinib

From: Syk inhibitors in clinical development for hematological malignancies

Phase

Diseases

Interventions

NCT ID

2

CLL, MCL, DLBCL, non-FL iNHL, FL

Entospletinib monotherapy

NCT01799889

1/2

AML

Entospletinib monotherapy

NCT02343939

2

CLL, MCL, DLBCL, iNHL

Entospletinib with idelalisib

NCT01796470

1

ALL

Entospletinib, vincristine, dexamethasone

NCT02404220

2

GVHD

Entospletinib, placebo, corticosteroids

NCT02701634

1

 

Entospletinib

NCT02521376

1

B-cell malignancies

Entospletinib, idelalisib, ONO/GS-4059

NCT02457598

1, 2

NHL

Entospletinib, vincristine

NCT02568683

  1. AML acute myelogenous leukemia, ALL acute lymphocytic leukemia, CLL chronic lymphocytic leukemia, DLBCL diffuse large B-cell lymphoma, FL follicular lymphoma, GVHD graft versus host disease, MCL mantle cell lymphoma, NHL non-Hodgkin lymphoma, iNHL indolent NHL